The recent work of Barry et al. demonstrated in two clinical studies of anti-PD-1 treated metastatic melanoma patients that the proportion of TA-cDC1 determined by flow cytometry is significantly higher in responders compared to non-responders [182]. This evidence concerns the gene MPPE1 and metastatic melanoma.